When did MEDIPHARM LABS CORP (LABS.CA) report earnings last quarter?
MEDIPHARM LABS CORP (LABS.CA) last reported earnings on 3/30/2026.
MEDIPHARM LABS CORP (LABS.CA) Earnings History & Surprises
TSX:LABS • CA58504D1006
Current stock price
0.09 CAD
+0.02 (+38.46%)
Last:
LABS.CA Earnings overview
Past quarterly earnings results for MEDIPHARM LABS CORP (LABS.CA), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- May 18, 2026
- Period
- Q1 / 2026
- EPS Estimate
- CA$0.00
- Revenue Estimate
- 8.871M
Last Reported
Most Recent- Release Date
- Mar 30, 2026
- Period
- Q4 / 2025
- EPS Reported
- -CA$0.01
- EPS Surprise
- -145.10%
- Revenue Surprise
- -8.27%
Beat Rate
Last 8 Quarters 31%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in CAD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -0.01 | 0.00 | -145.10% | 50.00% | 11.062M | 12.059M | -8.27% | -8.14% |
| Q3 2025 | -0.01 | 0.00 | -226.80% | - | 12.218M | 12.093M | 1.03% | 24.70% |
| Q2 2025 | -0.01 | 0.00 | -390.20% | - | 12.612M | 11.226M | 12.35% | 21.86% |
| Q1 2025 | 0.00 | 0.00 | 75.49% | 90.00% | 10.806M | 10.753M | 0.49% | 10.59% |
| Q4 2024 | -0.01 | 0.00 | - | - | 12.042M | 11.116M | 8.33% | 31.88% |
| Q3 2024 | -0.01 | 0.00 | - | - | 9.798M | 12.486M | -21.53% | 15.20% |
| Q2 2024 | -0.01 | -0.01 | 1.96% | - | 10.35M | 10.466M | -1.11% | 8.00% |
| Q1 2024 | -0.01 | -0.01 | 1.96% | - | 9.771M | 9.63M | 1.46% | 67.23% |
| Q4 2023 | -0.01 | -0.01 | 1.96% | 50.00% | 9.131M | 8.838M | 3.32% | 62.47% |
| Q3 2023 | -0.01 | -0.01 | -96.08% | 66.67% | 8.505M | 10.574M | -19.57% | 17.15% |
| Q2 2023 | -0.01 | -0.02 | 34.64% | 66.67% | 9.583M | 13.766M | -30.39% | 119.79% |
| Q1 2023 | -0.01 | -0.02 | 34.64% | 66.67% | 5.843M | 6.324M | -7.61% | 19.73% |
| Q4 2022 | -0.02 | -0.02 | -30.72% | 75.00% | 5.62M | 5.949M | -5.53% | -2.09% |
| Q3 2022 | -0.03 | -0.02 | -47.06% | - | 7.26M | 5.03M | 44.33% | 34.44% |
| Q2 2022 | -0.03 | -0.02 | -47.06% | 40.00% | 4.36M | 5.512M | -20.90% | -14.00% |
| Q1 2022 | -0.03 | -0.02 | -47.06% | 57.14% | 4.88M | 6.139M | -20.51% | -11.27% |
| Q4 2021 | -0.08 | -0.02 | -292.16% | 61.90% | 5.74M | 6.042M | -5.00% | -5.28% |
| Q3 2021 | -0.03 | -0.02 | -47.06% | 72.73% | 5.4M | 6.355M | -15.03% | 9.09% |
| Q2 2021 | -0.05 | -0.03 | -63.40% | -400.00% | 5.07M | 6.897M | -26.49% | -63.58% |
| Q1 2021 | -0.07 | -0.03 | -128.76% | -133.33% | 5.5M | 7.888M | -30.27% | -50.41% |
| Q4 2020 | -0.21 | -0.03 | -586.27% | - | 6.06M | 5.667M | 6.93% | - |
| Q3 2020 | -0.11 | -0.03 | -259.48% | - | 4.95M | 14.313M | -65.42% | - |
| Q2 2020 | -0.01 | -0.04 | 75.49% | - | 13.92M | 10.873M | 28.02% | - |
| Q1 2020 | -0.03 | -0.01 | -194.12% | - | 11.09M | 22.647M | -51.03% | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
1
Average EPS beat (4)
-171.65%
Max EPS beat (4)
75.49%
Min EPS beat (4)
-390.20%
Revenue beat statistics
Revenue beat (4)
3
Average Revenue beat (4)
1.40%
Max Revenue beat (4)
12.35%
Min Revenue beat (4)
-8.27%
Analysis
In the last 4 quarters, LABS.CA has beaten EPS estimates in 1 out of 4 releases
LABS.CA has beaten revenue estimates in 3 out of the last 4 releases
In the last 4 quarters, LABS.CA reported -171.7% below the EPS estimates on average.
In the last 4 quarters, LABS.CA has beaten the revenue estimates by 1.4% on average.
Related analysis
MEDIPHARM LABS CORP / LABS.CA Earnings FAQ
Did LABS stock beat earnings estimates in the most recent quarter?
MEDIPHARM LABS CORP (LABS.CA) missed EPS estimates and missed revenue estimates in the most recent quarter.
Can you provide information on how often MEDIPHARM LABS CORP beats earnings estimates?
In the last 4 quarters, MEDIPHARM LABS CORP (LABS.CA) has beaten EPS estimates in 1 out of 4 releases.